$RVPH
REVIVA PHARMACEUTICALS HOLDINGS, INC.

2024 Q1 Form 10-K Financial Statement

#000143774924011955 Filed on April 15, 2024

View on sec.gov

Income Statement

Concept 2024 Q1 2023 Q4 2023
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.138M $1.512M
YoY Change 42.5% 2.42%
% of Gross Profit
Research & Development $5.784M $8.476M $31.42M
YoY Change 10.48% 34.6% 65.82%
% of Gross Profit
Depreciation & Amortization $0.00
YoY Change
% of Gross Profit
Operating Expenses $7.922M $9.988M $39.50M
YoY Change 17.62% 28.49% 62.52%
Operating Profit -$7.922M -$39.50M
YoY Change 17.62% 62.52%
Interest Expense $3.487K $192.7K
YoY Change -54.45% 53.16%
% of Operating Profit
Other Income/Expense, Net $495.9K $66.76K $259.7K
YoY Change 264.66% -114.46% -2281.47%
Pretax Income -$7.426M -$9.729M -$39.24M
YoY Change 12.53% 19.96% 61.37%
Income Tax $7.396K -$4.580K $16.95K
% Of Pretax Income
Net Earnings -$7.400M -$9.724M -$39.30M
YoY Change 12.12% 19.78% 61.73%
Net Earnings / Revenue
Basic Earnings Per Share -$0.25 -$1.65
Diluted Earnings Per Share -$0.25 -$0.36
COMMON SHARES
Basic Shares Outstanding 27.92M 22.65M 23.80M
Diluted Shares Outstanding

Balance Sheet

Concept 2024 Q1 2023 Q4 2023
SHORT-TERM ASSETS
Cash & Short-Term Investments $11.97M $23.37M $23.37M
YoY Change 6.38% 26.18% 26.18%
Cash & Equivalents $11.97M $23.37M
Short-Term Investments
Other Short-Term Assets $1.523M $332.9K $332.9K
YoY Change -7.47% -17.55% -17.55%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $13.50M $23.70M $23.70M
YoY Change 4.61% 25.24% 25.24%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
TOTAL ASSETS
Total Short-Term Assets $13.50M $23.70M $23.70M
Total Long-Term Assets $0.00 $0.00 $0.00
Total Assets $13.50M $23.70M $23.70M
YoY Change 4.61% 25.24% 25.24%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.720M $3.849M $3.849M
YoY Change 99.98% 9.34% 9.34%
Accrued Expenses $8.440M $13.33M $13.33M
YoY Change 178.33% 428.9% 428.9%
Deferred Revenue
YoY Change
Short-Term Debt $332.0K $0.00 $0.00
YoY Change -50.26%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $14.49M $17.18M $17.18M
YoY Change 120.91% 184.36% 184.36%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $350.5K $806.7K $806.7K
YoY Change -37.0% 42.16% 42.16%
Total Long-Term Liabilities $350.5K $806.7K $806.7K
YoY Change -37.0% 42.16% 42.16%
TOTAL LIABILITIES
Total Short-Term Liabilities $14.49M $17.18M $17.18M
Total Long-Term Liabilities $350.5K $806.7K $806.7K
Total Liabilities $14.84M $17.98M $17.98M
YoY Change 108.56% 172.15% 172.15%
SHAREHOLDERS EQUITY
Retained Earnings -$141.8M -$134.4M
YoY Change 44.99% 47.37%
Common Stock $2.792K $2.792K
YoY Change 36.53% 36.53%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$1.346M $5.719M $5.719M
YoY Change
Total Liabilities & Shareholders Equity $13.50M $23.70M $23.70M
YoY Change 4.61% 25.24% 25.24%

Cashflow Statement

Concept 2024 Q1 2023 Q4 2023
OPERATING ACTIVITIES
Net Income -$7.400M -$9.724M -$39.30M
YoY Change 12.12% 19.78% 61.73%
Depreciation, Depletion And Amortization $0.00
YoY Change
Cash From Operating Activities -$11.73M -$8.876M -$28.32M
YoY Change 47.47% 89.24% 49.39%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $332.0K 27.27M $33.17M
YoY Change -51.68% 146837.5% 325.69%
NET CHANGE
Cash From Operating Activities -$11.73M -8.876M -$28.32M
Cash From Investing Activities
Cash From Financing Activities $332.0K 27.27M $33.17M
Net Change In Cash -$11.39M 18.40M $4.848M
YoY Change 56.85% -493.73% -143.41%
FREE CASH FLOW
Cash From Operating Activities -$11.73M -$8.876M -$28.32M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.65
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
8394246 usd
CY2023 rvph Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
5677850 usd
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
16949 usd
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0001742927
CY2023Q4 us-gaap Significant Change In Unrecognized Tax Benefits Is Reasonably Possible Amount Of Unrecorded Benefit
SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit
0 usd
CY2023Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0 usd
CY2023 us-gaap Income Tax Reconciliation Tax Credits
IncomeTaxReconciliationTaxCredits
0 usd
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2023Q4 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023Q4 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2023Q4 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
true
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
true
CY2023 dei Document Fin Stmt Restatement Recovery Analysis Flag
DocumentFinStmtRestatementRecoveryAnalysisFlag
false
CY2023 dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Public Float
EntityPublicFloat
103700000 usd
CY2024Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
27918560
CY2023 dei Auditor Name
AuditorName
Moss Adams LLP
CY2023 dei Auditor Location
AuditorLocation
San Francisco, California
CY2023 dei Auditor Firm
AuditorFirmId
659
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
23367456 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
18519856 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
332932 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
403819 usd
CY2023Q4 us-gaap Assets
Assets
23700388 usd
CY2022Q4 us-gaap Assets
Assets
18923675 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3849108 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3520271 usd
CY2023Q4 rvph Accrued Liabilities And Other Current Liabilities
AccruedLiabilitiesAndOtherCurrentLiabilities
11966812 usd
CY2022Q4 rvph Accrued Liabilities And Other Current Liabilities
AccruedLiabilitiesAndOtherCurrentLiabilities
5578374 usd
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
958607 usd
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
564646 usd
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
400490 usd
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
298699 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
17175017 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
9961990 usd
CY2023Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
806655 usd
CY2022Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
567439 usd
CY2023Q4 us-gaap Liabilities
Liabilities
17981672 usd
CY2022Q4 us-gaap Liabilities
Liabilities
10529429 usd
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
115000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
115000000
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
27918560
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
27918560
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
20447371
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
20447371
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
2792 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
2045 usd
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
140070172 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
103485612 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-134354248 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-95093411 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
5718716 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
8394246 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
23700388 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
18923675 usd
CY2023 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
31419817 usd
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
22870024 usd
CY2023 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8083819 usd
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5358734 usd
CY2022 us-gaap Operating Expenses
OperatingExpenses
28228758 usd
CY2023 rvph Interest And Other Income Expense Net
InterestAndOtherIncomeExpenseNet
498964 usd
CY2022 rvph Interest And Other Income Expense Net
InterestAndOtherIncomeExpenseNet
182802 usd
CY2023 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
259748 usd
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-11907 usd
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-39243888 usd
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-28240665 usd
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
20777 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-39260837 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-28261442 usd
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.45
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
23798203
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
19516479
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
28686460 usd
CY2022 rvph Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
18966 usd
CY2022 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
7773527 usd
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
176735 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-28261442 usd
CY2023 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
27494103 usd
CY2023 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3413354 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-39260837 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
5718716 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-39260837 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-28261442 usd
CY2023 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
239216 usd
CY2022 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
194709 usd
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
3413354 usd
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
176735 usd
CY2023 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-70887 usd
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1312238 usd
CY2023 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
328837 usd
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3010688 usd
CY2023 rvph Increase Decrease In Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
6884190 usd
CY2022 rvph Increase Decrease In Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
4606491 usd
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-28324353 usd
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-18960581 usd
CY2023 us-gaap Proceeds From Short Term Debt
ProceedsFromShortTermDebt
667500 usd
CY2022 us-gaap Proceeds From Short Term Debt
ProceedsFromShortTermDebt
0 usd
CY2023 us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
667500 usd
CY2022 us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
-0 usd
CY2023 rvph Proceeds From Issuance Or Sale Of Equity Net
ProceedsFromIssuanceOrSaleOfEquityNet
27494103 usd
CY2022 rvph Proceeds From Issuance Or Sale Of Equity Net
ProceedsFromIssuanceOrSaleOfEquityNet
7773527 usd
CY2023 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
5677850 usd
CY2022 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
18966 usd
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
33171953 usd
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
7792493 usd
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
4847600 usd
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-11168088 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
18519856 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
29687944 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
23367456 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
18519856 usd
CY2023 us-gaap Income Taxes Paid
IncomeTaxesPaid
19754 usd
CY2022 us-gaap Income Taxes Paid
IncomeTaxesPaid
16484 usd
CY2023 us-gaap Interest Paid Net
InterestPaidNet
30622 usd
CY2022 us-gaap Interest Paid Net
InterestPaidNet
0 usd
CY2022Q4 rvph Accrued Clinical Expenses
AccruedClinicalExpenses
5578374 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
9961990 usd
CY2022Q4 us-gaap Liabilities
Liabilities
10529429 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-95093411 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
8394246 usd
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
22870024 usd
CY2022 us-gaap Operating Expenses
OperatingExpenses
28228758 usd
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-28228758 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-28261442 usd
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.45
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-28261442 usd
CY2022 rvph Increase Decrease In Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
4606491 usd
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-18960581 usd
CY2023 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><span style="text-decoration: underline; ">Reclassification</span></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Certain amounts in the prior year’s consolidated financial statements related to accrued clinical expenses and accrued compensation from accrued liabilities have been reclassified to conform to the current year’s presentation. This involved disclosing separately, accrued clinical expenses, accrued compensation and other accrued liabilities, which were previously disclosed in the aggregate, as accrued expenses and other current liabilities. These reclassifications had no effect on the Company’s loss from operations, net loss, and net loss per share.</p>
CY2023Q4 rvph Working Capital
WorkingCapital
6500000 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-134400000 usd
CY2023Q4 us-gaap Cash
Cash
23400000 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-39300000 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-28300000 usd
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">Use of estimates</span></p> <p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;"> </p> <p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt; text-align: justify;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of expenses during the reporting periods covered by the consolidated financial statements and accompanying notes. Significant areas requiring the use of management estimates include, but are not limited to, accounting for research and development activities, assumptions used to calculate the fair value of stock-based compensation, assumptions used to calculate the fair value of warrant liabilities, deferred taxes, and related valuation allowances. Actual results could differ materially from such estimates under different assumptions or circumstances.</p>
CY2023 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;"><span style="text-decoration: underline; ">Concentration of credit risk and other risks and uncertainties</span></p> <p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents. Substantially, all the Company’s cash and cash equivalents are held in demand deposit form at three financial institutions. Deposits in financial institutions may, from time to time, exceed federally insured limits. The Company has not experienced any losses on its deposits of cash.</p> <p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company is subject to all of the risks inherent in an early-stage company developing new pharmaceutical products. These risks include, but are not limited to, limited management resources, dependence upon medical acceptance of the product in development, regulatory approvals, successful clinical trials, availability and willingness of patients to participate in human trials, and competition in the pharmaceutical industry. The Company’s operating results may be materially affected by the foregoing factors.</p>
CY2023 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
22464443
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
18477878
CY2021Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
16169969
CY2021Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
7.41
CY2021 rvph Class Of Warrant Or Right Outstanding Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm
P4Y1M6D
CY2022 rvph Class Of Warrant Or Right Issued During Period
ClassOfWarrantOrRightIssuedDuringPeriod
4743083
CY2022 rvph Class Of Warrant Or Right Issued During Period Exercise Price
ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice
1.7
CY2022 rvph Class Of Warrant Or Right Issued In Period Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightIssuedInPeriodWeightedAverageRemainingContractualTerm
P3Y6M
CY2022 rvph Class Of Warrant Or Right Exercised During Period
ClassOfWarrantOrRightExercisedDuringPeriod
6000
CY2022 rvph Class Of Warrant Or Right Exercised In Period Exercise Price
ClassOfWarrantOrRightExercisedInPeriodExercisePrice
0
CY2022Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
20907052
CY2022Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
6.12
CY2022Q4 rvph Class Of Warrant Or Right Intrinsic Value
ClassOfWarrantOrRightIntrinsicValue
13244723 usd
CY2022 rvph Class Of Warrant Or Right Outstanding Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm
P3Y2M12D
CY2023 rvph Class Of Warrant Or Right Issued During Period
ClassOfWarrantOrRightIssuedDuringPeriod
6439026
CY2023 rvph Class Of Warrant Or Right Issued During Period Exercise Price
ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice
4.55
CY2023 rvph Class Of Warrant Or Right Issued In Period Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightIssuedInPeriodWeightedAverageRemainingContractualTerm
P5Y
CY2023 rvph Class Of Warrant Or Right Exercised During Period
ClassOfWarrantOrRightExercisedDuringPeriod
2278435
CY2023 rvph Class Of Warrant Or Right Exercised In Period Exercise Price
ClassOfWarrantOrRightExercisedInPeriodExercisePrice
0
CY2023Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
25067643
CY2023Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
6.03
CY2023Q4 rvph Class Of Warrant Or Right Intrinsic Value
ClassOfWarrantOrRightIntrinsicValue
29686123 usd
CY2023 rvph Class Of Warrant Or Right Outstanding Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm
P3Y1M6D
CY2022Q3 us-gaap Share Price
SharePrice
2.2
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
115000000
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
27918560
CY2023 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3400000 usd
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
200000 usd
CY2023Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
3400000 usd
CY2023 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y6M
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0 pure
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0 pure
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0 pure
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0 pure
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.59
CY2023 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3413354 usd
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
176735 usd
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-39301700 usd
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-28284894 usd
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
57812 usd
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
44229 usd
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-39243888 usd
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-28240665 usd
CY2023 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0 usd
CY2022 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0 usd
CY2023 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
2400 usd
CY2022 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
9277 usd
CY2023 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
14549 usd
CY2022 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
11500 usd
CY2023 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
16949 usd
CY2022 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
20777 usd
CY2023 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
0 usd
CY2022 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
0 usd
CY2023 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
0 usd
CY2022 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
0 usd
CY2023 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
0 usd
CY2022 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
0 usd
CY2023 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0 usd
CY2022 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0 usd
CY2023 rvph Income Tax Expense Benefit Including Immaterial Differences
IncomeTaxExpenseBenefitIncludingImmaterialDifferences
16949 usd
CY2022 rvph Income Tax Expense Benefit Including Immaterial Differences
IncomeTaxExpenseBenefitIncludingImmaterialDifferences
20777 usd
CY2023 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-8219715 usd
CY2022 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-5927545 usd
CY2023 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-91612 usd
CY2022 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
4424 usd
CY2023 rvph Effective Income Tax Rate Reconciliation Warrant Expense Amount
EffectiveIncomeTaxRateReconciliationWarrantExpenseAmount
50235 usd
CY2022 rvph Effective Income Tax Rate Reconciliation Warrant Expense Amount
EffectiveIncomeTaxRateReconciliationWarrantExpenseAmount
48653 usd
CY2023 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
86635 usd
CY2022 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
10766 usd
CY2023 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
2312 usd
CY2022 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
2211 usd
CY2022 us-gaap Income Tax Reconciliation Tax Credits
IncomeTaxReconciliationTaxCredits
28756 usd
CY2023 rvph Effective Income Tax Rate Reconciliation Other Permanent Adjustments Amount
EffectiveIncomeTaxRateReconciliationOtherPermanentAdjustmentsAmount
17498 usd
CY2022 rvph Effective Income Tax Rate Reconciliation Other Permanent Adjustments Amount
EffectiveIncomeTaxRateReconciliationOtherPermanentAdjustmentsAmount
9341 usd
CY2023 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
8204250 usd
CY2022 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
5781726 usd
CY2023 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
-32654 usd
CY2022 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
62445 usd
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
16949 usd
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
20777 usd
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
15264557 usd
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
12701772 usd
CY2023Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
231425 usd
CY2022Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
117909 usd
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
848987 usd
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
218421 usd
CY2023Q4 rvph Deferred Tax Assets Property Plant And Equipment And Start Up Costs
DeferredTaxAssetsPropertyPlantAndEquipmentAndStartUpCosts
0 usd
CY2022Q4 rvph Deferred Tax Assets Property Plant And Equipment And Start Up Costs
DeferredTaxAssetsPropertyPlantAndEquipmentAndStartUpCosts
2419 usd
CY2023Q4 rvph Deferred Tax Assets Capitalized Research And Development
DeferredTaxAssetsCapitalizedResearchAndDevelopment
11017511 usd
CY2022Q4 rvph Deferred Tax Assets Capitalized Research And Development
DeferredTaxAssetsCapitalizedResearchAndDevelopment
4280847 usd
CY2023Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
131090 usd
CY2022Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
5250 usd
CY2023Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
27493570 usd
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
17326618 usd
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
27493570 usd
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
17326618 usd
CY2023Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 usd
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 usd
CY2023Q4 rvph Deferred Income Taxes
DeferredIncomeTaxes
0 usd
CY2022Q4 rvph Deferred Income Taxes
DeferredIncomeTaxes
0 usd
CY2023 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
10166952 usd
CY2023Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
800000 usd
CY2022Q3 rvph Accrued Clinical Expenses
AccruedClinicalExpenses
3434159 usd
CY2023Q1 rvph Accrued Clinical Expenses
AccruedClinicalExpenses
6382558 usd
CY2023Q2 rvph Accrued Clinical Expenses
AccruedClinicalExpenses
8697594 usd
CY2023Q3 rvph Accrued Clinical Expenses
AccruedClinicalExpenses
10502498 usd
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
6379422 usd
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
10731533 usd
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
12644727 usd
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
17324351 usd
CY2022Q3 us-gaap Liabilities
Liabilities
6485121 usd
CY2023Q1 us-gaap Liabilities
Liabilities
11287846 usd
CY2023Q2 us-gaap Liabilities
Liabilities
13657217 usd
CY2023Q3 us-gaap Liabilities
Liabilities
18197762 usd
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-85856679 usd
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-101945100 usd
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-113653048 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-124998984 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
17555829 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
1613677 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-1815195 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-12810721 usd
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4240943 usd
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5484145 usd
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8256336 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9572180 usd
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
5497915 usd
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
6984699 usd
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
11335637 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
11563954 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-5497915 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-6984699 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-11335637 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-11563954 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-5450270 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-6851689 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-11707948 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-11345936 usd
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.28
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.31
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.52
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.48
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15454078 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13740481 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
23312661 usd
us-gaap Operating Expenses
OperatingExpenses
19336288 usd
us-gaap Operating Expenses
OperatingExpenses
18320336 usd
us-gaap Operating Expenses
OperatingExpenses
29884290 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-19336288 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-18320336 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-29884290 usd
us-gaap Net Income Loss
NetIncomeLoss
-19024710 usd
us-gaap Net Income Loss
NetIncomeLoss
-18559637 usd
us-gaap Net Income Loss
NetIncomeLoss
-29905573 usd
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.02
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.84
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.32
us-gaap Net Income Loss
NetIncomeLoss
-19024710 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-6851689 usd
us-gaap Net Income Loss
NetIncomeLoss
-18559637 usd
us-gaap Net Income Loss
NetIncomeLoss
-29905573 usd
rvph Increase Decrease In Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
2196396 usd
CY2023Q1 rvph Increase Decrease In Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
761736 usd
rvph Increase Decrease In Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
3332221 usd
rvph Increase Decrease In Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
5381757 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-14269947 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7951397 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-13268624 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-19447908 usd

Files In Submission

Name View Source Status
0001437749-24-011955-index-headers.html Edgar Link pending
0001437749-24-011955-index.html Edgar Link pending
0001437749-24-011955.txt Edgar Link pending
0001437749-24-011955-xbrl.zip Edgar Link pending
ex_643354.htm Edgar Link pending
ex_643355.htm Edgar Link pending
ex_643356.htm Edgar Link pending
ex_643357.htm Edgar Link pending
ex_643358.htm Edgar Link pending
ex_643359.htm Edgar Link pending
ex_643952.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
g01.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rvph-20231231.xsd Edgar Link pending
rvph20231231_10k.htm Edgar Link pending
rvph20231231_10kimg002.jpg Edgar Link pending
rvph20231231_10kimg003.jpg Edgar Link pending
rvph20231231_10kimg004.jpg Edgar Link pending
rvph20231231_10kimg005.jpg Edgar Link pending
rvph20231231_10kimg006.jpg Edgar Link pending
rvph20231231_10kimg007.jpg Edgar Link pending
rvph20231231_10kimg008.jpg Edgar Link pending
rvph20231231_10kimg009.jpg Edgar Link pending
rvph20231231_10kimg010.jpg Edgar Link pending
rvph20231231_10kimg011.jpg Edgar Link pending
rvph20231231_10kimg012.jpg Edgar Link pending
rvph20231231_10kimg013.jpg Edgar Link pending
rvph20231231_10kimg014.jpg Edgar Link pending
rvph20231231_10kimg015.jpg Edgar Link pending
rvph20231231_10kimg016.jpg Edgar Link pending
rvph20231231_10kimg017.jpg Edgar Link pending
rvph20231231_10kimg018.jpg Edgar Link pending
rvph20231231_10kimg019.jpg Edgar Link pending
rvph20231231_10kimg020.jpg Edgar Link pending
rvph20231231_10kimg021.jpg Edgar Link pending
rvph20231231_10kimg022.jpg Edgar Link pending
rvph20231231_10kimg023.jpg Edgar Link pending
rvph20231231_10kimg024.jpg Edgar Link pending
rvph20231231_10kimg025.jpg Edgar Link pending
rvph20231231_10kimg026.jpg Edgar Link pending
rvph20231231_10kimg027.jpg Edgar Link pending
rvph20231231_10kimg028.jpg Edgar Link pending
rvph20231231_10kimg029.jpg Edgar Link pending
rvph20231231_10kimg030.jpg Edgar Link pending
rvph20231231_10kimg031.jpg Edgar Link pending
Show.js Edgar Link pending
rvph-20231231_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
rvph-20231231_cal.xml Edgar Link unprocessable
rvph-20231231_def.xml Edgar Link unprocessable
rvph-20231231_lab.xml Edgar Link unprocessable
rvph20231231_10k_htm.xml Edgar Link completed